Form 4: Neurocrine Biosciences Director Stephen Sherwin Sells Shares Under 10b5-1 Trading Plan

Director Stephen Sherwin sold 13,831 shares of Neurocrine Biosciences (NBIX) common stock at an average price of $116.6888 under a pre-arranged 10b5-1 trading plan.

Summary

• On February 13, 2025, Stephen Sherwin, a director of Neurocrine Biosciences Inc. (NBIX), sold 13,831 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2024.
• The shares were sold at a weighted average price of $116.6888, with individual transactions ranging from $115.79 to $118.33.
• Following the transaction, Sherwin directly owns 10,673 shares of Neurocrine Biosciences.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by a director under a pre-arranged trading plan, which is neither particularly positive nor negative. The sentiment is neutral.

Industry Context

Sales by insiders are a common occurrence, and sales executed under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled. Investors often monitor insider transactions for signals about a company's prospects, but 10b5-1 sales are typically less informative.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Stephen Sherwin, Form 4, Stock Sale, 10b5-1 Trading Plan, Director, Insider Trading